abiraterone has been researched along with zoledronic acid in 13 studies
| Studies (abiraterone) | Trials (abiraterone) | Recent Studies (post-2010) (abiraterone) | Studies (zoledronic acid) | Trials (zoledronic acid) | Recent Studies (post-2010) (zoledronic acid) |
|---|---|---|---|---|---|
| 942 | 97 | 854 | 4,108 | 620 | 2,610 |
| Protein | Taxonomy | abiraterone (IC50) | zoledronic acid (IC50) |
|---|---|---|---|
| Carbonic anhydrase 12 | Homo sapiens (human) | 0.316 | |
| Geranylgeranyl pyrophosphate synthase | Homo sapiens (human) | 0.318 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.062 | |
| 72 kDa type IV collagenase | Homo sapiens (human) | 7 | |
| Farnesyl pyrophosphate synthase | Homo sapiens (human) | 0.2144 | |
| Farnesyl diphosphate synthase | Escherichia coli K-12 | 1.1 | |
| Farnesyl pyrophosphate synthase | Leishmania donovani | 0.11 | |
| Geranylgeranyl pyrophosphate synthase | Saccharomyces cerevisiae S288C | 0.424 | |
| Carbonic anhydrase 9 | Homo sapiens (human) | 5.323 | |
| Carbonic anhydrase 14 | Homo sapiens (human) | 0.092 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 5 (38.46) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Higano, CS | 1 |
| D'Amico, AV | 1 |
| Gartrell, BA; Saad, F | 1 |
| Beer, TM; Graff, JN | 1 |
| Bertaglia, V; Buttigliero, C; Di Maio, M; Scagliotti, GV; Tucci, M; Vignani, F | 1 |
| Saad, F; Traboulsi, SL | 1 |
| Chouahnia, K; Culine, S; Fossey-Diaz, V; Guetz, GD; Landre, T; Taleb, C | 1 |
| George, DJ; Higano, CS; Jiao, X; Kalinovsky, J; Miller, K; Saad, F; Sartor, O; Shore, N; Sternberg, CN; Tangirala, K; Tombal, B | 1 |
| Bourlon, C; Bourlon, MT; Carretero-Gonzalez, A; Carril-Ajuria, L; Castellano, D; de Velasco, G; Martin-Soberon, M; Remolina-Bonilla, YA | 1 |
| Griebling, TL | 1 |
| Anton, A; Azad, A; Gibbs, P; Goh, J; Gunjur, A; Kwan, EM; Parente, P; Parnis, F; Pezaro, C; Semira, MC; Shapiro, J; Spain, L; Torres, J; Tran, B; Weickhardt, A; Wong, S | 1 |
| Anderson, M; Cao, Y; Chang, M; Rojas, V; Trieu, J; Varada, N; Vogelzang, NJ | 1 |
6 review(s) available for abiraterone and zoledronic acid
| Article | Year |
|---|---|
Pathologic fracture in patients with metastatic prostate cancer.
Topics: Androstenes; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Zoledronic Acid | 2014 |
Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
Topics: Androgen Receptor Antagonists; Androstenes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Enzyme Inhibitors; Fractures, Spontaneous; Humans; Imidazoles; Male; Nitriles; Pain; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Spinal Cord Compression; Zoledronic Acid | 2015 |
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Topics: Androstenes; Anilides; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Dasatinib; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Taxoids; Zoledronic Acid | 2016 |
The role of bone-targeted therapies for prostate cancer in 2017.
Topics: Androstenes; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Male; Prospective Studies; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Zoledronic Acid | 2017 |
Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Prostatic Neoplasms; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2019 |
Lower Fracture Rates in Patients Treated with Radium-223, Abiraterone or Enzalutamide, When Given Concurrently with Bone Health Agents: A Real-World Analysis.
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Density; Denosumab; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Zoledronic Acid | 2022 |
7 other study(ies) available for abiraterone and zoledronic acid
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
New treatment options for patients with metastatic castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Zoledronic Acid | 2012 |
US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Denosumab; Diphosphonates; Docetaxel; Drug Approval; Drugs, Investigational; Estramustine; Goserelin; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Oligopeptides; Phenylthiohydantoin; Prostatic Neoplasms; Radioisotopes; Radium; Taxoids; Tissue Extracts; United States; United States Food and Drug Administration; Zoledronic Acid | 2014 |
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Denosumab; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid | 2020 |
Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic.
Topics: Aged; Androgen Antagonists; Androstenes; Anticoagulants; Antineoplastic Agents; Betacoronavirus; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Coronavirus Infections; COVID-19; Disease Progression; Docetaxel; Drug Combinations; Eligibility Determination; Heparin, Low-Molecular-Weight; Humans; Intensive Care Units; Lopinavir; Male; Oxygen Inhalation Therapy; Palliative Care; Pandemics; Pneumonia, Viral; Prostatic Neoplasms, Castration-Resistant; Renal Insufficiency; Respiratory Insufficiency; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Severity of Illness Index; Zoledronic Acid | 2020 |
Re: Is There a Benefit of Additional Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years with Hormone-Sensitive Advanced Prostate Cancer? A Meta-Analysis.
Topics: Androstenes; Celecoxib; Docetaxel; Humans; Male; Prostatic Neoplasms; Zoledronic Acid | 2020 |
Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Australia; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Docetaxel; Humans; Incidence; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2021 |